SpringerLink
Log in

Vaccination Strategies in Solid Organ and Stem Cell Transplant

  • Reference work entry
  • First Online:
Emerging Transplant Infections

  • 1146 Accesses

Abstract

Solid organ and hematopoietic stem cell transplant recipients are at high risk of contracting infectious diseases, including vaccine-preventable illnesses, in the post-transplant period. Given the high degree of immunosuppression immediately post-transplant, infection in the transplant patient results in higher morbidity and mortality than in the general population. Thus, it is the responsibility of the care team to ensure appropriate vaccines are given in an attempt to mitigate this risk. Timing of vaccination in the solid organ or hematopoietic stem cell transplant recipient is critical in order to strike a balance between providing protection against vaccine-preventable illnesses as early as possible, and vaccinating at a time when it is safe and the host’s immune response to vaccination will be adequate. This chapter will focus on providing a rationale for and summary of the specific recommendations pertaining to vaccination of both the solid organ and hematopoietic stem cell transplant recipient.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 699.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 899.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Mawhinney H, Allen IV, Beare JM, et al. Dysgammaglobulinemia complicated by disseminated measles. Br Med J. 1971;2:380–1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Mitus A, Holloway A, Evans AE, Enders JF. Attenuated measles vaccine in children with acute leukemia. Am J Dis Child. 1962;103:413–8.

    CAS  PubMed  Google Scholar 

  3. Kobashigawa JA, Warner L, Stevenson BL, et al. Influenza vaccine does not cause rejection after cardiac transplantation. Transplant Proc. 1993;25:2738–9.

    CAS  PubMed  Google Scholar 

  4. Kimball P, Verbeke S, Flattery M, Rhodes C, Tolman D. Influenza vaccination does not promote cellular or humoral activation among heart transplant recipients. Transplantation. 2000;69:2449–51.

    Article  CAS  PubMed  Google Scholar 

  5. Magnani G, Falchetti E, Pollini G, et al. Safety and efficacy of two types of influenza vaccination in heart transplant recipients: a prospective randomized controlled study. J Heart Lung Transplant. 2005;24:588–92.

    Article  PubMed  Google Scholar 

  6. Danziger-Isakov L, Kumar D. Vaccination of solid organ transplant candidates and recipients: guidelines from the American society of transplantation infectious diseases community of practice. Clin Transpl. 2019;33:e13563. https://doi.org/10.1111/ctr.13563.

    Article  Google Scholar 

  7. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15:1143–238.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Kumar D, Ferreria VH, Blumberg E, et al. A 5-year prospective multicenter evaluation of influenza infection in transplant recipients. Clin Infect Dis. 2018;67:1322–9.

    Article  PubMed  Google Scholar 

  9. Ljungman P, de la Camara R, Perez-Bercoff L, Infectious Diseases Working Party, European Group for Blood and Marrow Transplantation, Infectious Complications Subcommittee, Spanish Group of Hematopoietic Stem-Cell Transplantation, et al. Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients. Hematologica. 2011;96:1231–5.

    Google Scholar 

  10. Kmeid J, Vanichanan J, Shah DP, et al. Outcomes of influenza infections in hematopoietic stem cell transplant recipients: an application of an immunodeficiency scoring index. Biol Blood Marrow Transplant. 2016;22:542–8.

    Article  PubMed  Google Scholar 

  11. Reid G, Huprikar S, Patel G, et al. A multicenter evaluation of pandemic influenza A/H1N1 in hematopoietic stem cell transplant recipients. Transpl Infect Dis. 2013;15:487–92.

    Google Scholar 

  12. Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58:309–18.

    Article  PubMed  Google Scholar 

  13. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9(Suppl 3):S1–S157.

    Google Scholar 

  14. Baluch A, Humar A, Eurich D, et al. Randomized controlled trial of high-dose intradermal versus standard-dose intramuscular influenza vaccine in organ transplant recipients. Am J Transplant. 2013;13:1026–33.

    Article  CAS  PubMed  Google Scholar 

  15. Mulley WR, Dendle C, Ling JEH, Knight SR. Does vaccination in solid-organ transplant recipients result in adverse immunologic sequelae? A systematic review and meta-analysis. J Heart Lung Transplant. 2018;37:844–52.

    Article  PubMed  Google Scholar 

  16. Kumar D, Blumberg EA, Danziger-Isakov L, et al. Influenza vaccination in the organ transplant recipient: review and summary recommendations. Am J Transplant. 2011;11:2020–30.

    Article  CAS  PubMed  Google Scholar 

  17. Arnou R, Eavis P, Pardo JR, Ambrozaitis A, Kazek MP, Weber F. Immunogenicity, large scale safety and lot consistency of an intra-dermal influenza vaccine in adults aged 18–60 years: randomized, controlled, phase III trial. Hum Vaccin. 2010;6:346–54.

    Article  PubMed  Google Scholar 

  18. Kumar D, Campbell P, Hoschler K, et al. Randomized controlled trial of adjuvanted versus nonadjuvanted influenza vaccine in kidney transplant recipients. Transplantation. 2016;100:662–9.

    Article  CAS  PubMed  Google Scholar 

  19. Cordero E, Roca-Oporto C, Bulnes-Ramos A, et al. Two doses of inactivated influenza vaccine improve immune response in solid organ transplant recipients: results of TRANSGRIPE 1-2, a randomized controlled clinical trial. Clin Infect Dis. 2017;64:829–38.

    Article  CAS  PubMed  Google Scholar 

  20. Natori Y, Shiotsuka M, Slomovic J, et al. A double-blind, randomized trial of high-dose vs standard-dose influenza vaccine in adult solid-organ transplant recipients. Clin Infect Dis. 2018;66:1698–704.

    Article  CAS  PubMed  Google Scholar 

  21. Cordonnier C, Einarsdottir S, Cesaro S, et al. Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European conference of infections in leukemia (ECIL-7). Lancet Infect Dis. 2019; https://doi.org/10.1016/S1472-3099(18)30600-5.

  22. Issa NC, Marty FM, Gagne LS, et al. Seroprotective titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2011;17:434–8.

    Article  PubMed  Google Scholar 

  23. Engelhard D, Nagler A, Hardan I, et al. Antibody response to a two-dose regimen of influenza vaccine in allogeneic T-cell depleted and autologous BMT recipients. Bone Marrow Transplant. 1993;11:1–5.

    CAS  PubMed  Google Scholar 

  24. Natori Y, Humar A, Lipton J, et al. A pilot randomized trial of adjuvanted influenza vaccine in adult allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2017;52:1016–21.

    Article  CAS  PubMed  Google Scholar 

  25. Mohty B, Bel M, Vukicevic M, et al. Graft-versus-host disease is the major determinant of humoral responses to the AS03-adjuvanted influenza A/09/H1N1 vaccine in allogeneic hematopoietic stem cell transplant recipients. Haematologica. 2011;96:896–904.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Fukatsu Y, Nagata Y, Adachi M, Yagu T, Ono T. Serum IgM levels independently predict immune response to influenza vaccine in long-term survivors vaccinated at > 1 year after undergoing allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2017;105:638–45.

    Article  CAS  PubMed  Google Scholar 

  27. Karras NA, Weeres M, Sessions W, et al. A randomized trial of one versus two doses of influenza vaccine after allogeneic transplantation. Biol Blood Marrow Transplant. 2013;19:109–16.

    Article  PubMed  Google Scholar 

  28. Pauksen K, Linde A, Hammarstrom V, et al. Granulocyte-macrophage colony-stimulating factor as immunomodulating factor together with influenza vaccination in stem cell transplant recipients. Clin Infect Dis. 2000;30:342–8.

    Article  CAS  PubMed  Google Scholar 

  29. Ambati A, Boas LS, Ljungman P, et al. Evaluation of pretransplant influenza vaccination in hematopoietic SCT: a randomized prospective study. Bone Marrow Transplant. 2015;50:858–64.

    Article  CAS  PubMed  Google Scholar 

  30. Halasa NM, Savani BN, Asokan I, et al. Randomized double-blind study of the safety and immunogenicity of standard-dose trivalent inactivated influenza vaccine versus high-dose trivalent inactivated influenza vaccine in hematopoietic stem cell transplant patients. Biol Blood Marrow Transplant. 2016;22:528–35.

    Article  CAS  PubMed  Google Scholar 

  31. Kumar D, Humar A, Plevneshi A, et al. Invasive pneumococcal disease in solid organ transplant recipients – 10-year prospective population surveillance. Am J Transplant. 2007;7:1209–14.

    Article  CAS  PubMed  Google Scholar 

  32. Kulkarni S, Powles R, Treleaven J, et al. Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants. Blood. 2000;95:3683–6.

    Article  CAS  PubMed  Google Scholar 

  33. Dendle C, Stuart RL, Mulley WR, Holdsworth SR, et al. Pneumococcal vaccination in adult solid organ transplant recipients: a review of current evidence. Vaccine. 2018;36:6253–61.

    Article  PubMed  Google Scholar 

  34. Kumar D, Rotstein C, Miyata G, Arlen D, Humar A. Randomized, double-blinded, controlled trial of pneumococcal vaccination in renal transplant recipients. J Infect Dis. 2003;187:1639–45.

    Article  PubMed  Google Scholar 

  35. Kumar D, Welsh B, Siegal D, Chen MH, Humar A. Immunogenicity of pneumococcal vaccine in renal transplant recipients – three year follow-up of a randomized trial. Am J Transplant. 2007;7:633–8.

    Article  CAS  PubMed  Google Scholar 

  36. Dendle C, Stuart RL, Polkinghorne KR, et al. Seroresponses and safety of 13-valent pneumococcal conjugate vaccination in kidney transplant recipients. Transpl Infect Dis. 2018;20:e12866. https://doi.org/10.1111/tid.12866.

    Article  CAS  PubMed  Google Scholar 

  37. Kumar D, Chen MH, Wong G, et al. A randomized, double-blind, placebo-controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in adult liver transplant recipients. Clin Infect Dis. 2008;47:885–92.

    Article  PubMed  Google Scholar 

  38. Tobudic S, Plunger V, Sunder-Plassmann G, Riegersperger M, Burgmann H. Randomized, single blind, controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in renal transplant recipients. PLoS One. 2012;7:e46133. https://doi.org/10.1371/journalpone.0046133.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Barton M, Wasfy S, Dipchand AI, et al. Seven-valent pneumococcal conjugate vaccine in pediatric solid organ transplant recipients. Pediatr Infect Dis J. 2009;28:688–92.

    Article  PubMed  Google Scholar 

  40. Kobayashi M, Bennet N, Gierke R, et al. Intervals between PCV13 and PPSV23 vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2015;64:944–7.

    Article  PubMed  Google Scholar 

  41. Kumar D, Humar A, Plevneshi A, et al. Invasive pneumococcal disease in adult hematopoietic stem cell transplant recipients: a decade of prospective population-based surveillance. Bone Marrow Transplant. 2008;41:743–7.

    Article  CAS  PubMed  Google Scholar 

  42. Engelhard D, Cordonnier C, Shaw PJ, et al. Early and late invasive pneumococcal infection following stem cell transplantation: a European Bone Marrow Transplantation survey. Br J Haematol. 2002;117:444–50.

    Article  PubMed  Google Scholar 

  43. Debbache K, Varon E, Hicheri Y, et al. The epidemiology of invasive Streptococcus pneumoniae infections in onco-haematology and haematopoietic stem cell transplant patients in France. Are the serotypes covered by the available anti-pneumococcal vaccines? Clin Microbiol Infect. 2009;15:865–8.

    Article  CAS  PubMed  Google Scholar 

  44. Guinan EC, Molrine DC, Antin JH, et al. Polysaccharide conjugate vaccine responses in bone marrow transplant patients. Transplantation. 1994;57:677–84.

    Article  CAS  PubMed  Google Scholar 

  45. Kumar D, Chen MH, Welsh B, et al. A randomized, double-blind trial of pneumococcal vaccination in adult allogeneic stem cell transplant donors and recipients. Clin Infect Dis. 2007;45:1576–82.

    Article  PubMed  Google Scholar 

  46. Cordonnier C, Labopin M, Chesnel V, et al. Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation. Clin Infect Dis. 2009;48:1392–401.

    Article  CAS  PubMed  Google Scholar 

  47. Cordonnier C, Labopin M, Chesnel V, et al. Immune response to the 23-valent polysaccharide pneumococcal vaccine after the 7-valent conjugate vaccine in allogeneic stem cell transplant recipients: results from the EBMT IDWP01 trial. Vaccine. 2010;28:2730–4.

    Article  CAS  PubMed  Google Scholar 

  48. Cordonnier C, Ljungman P, Juergens C, et al. Immunogenicity, safety, and tolerability of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in recipients of allogeneic hematopoietic stem cell transplant aged ≥ 2 years: an open-label study. Clin Infect Dis. 2015;61:313–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. CDC. Meningococcal disease. Atlanta: US Department of Health and Human Services. CDC; 2017. https://www.cdc.gov/meningococcal/surveillance/index.html

  50. Kotton CN, Hibberd PL, The AST Infectious Diseases Community of Practice. Travel medicine and transplant tourism in solid organ transplantation. Am J Transplant. 2013;13:337–47.

    Article  CAS  PubMed  Google Scholar 

  51. Food and Drug Administration. Alexion briefing information for the November 18, 2014, meeting of the Drug Safety and Risk Management Advisory Committee. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSDrugSafetyandRiskManagementAdvisoryComm/ucm423029.htm

  52. CDC. Meningococcal ACIP recommendations. Atlanta: US Department of Health and Human Services. CDC; 2017. https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mening.html

  53. Struijk GH, Bouts AHM, Rijkers GT, Kuin EAC, ten Berge IJM, Bemelman FJ. Meningococcal sepsis complicating eculizumab treatment despite prior vaccination. Am J Transplant. 2013;13:819–20.

    Article  CAS  PubMed  Google Scholar 

  54. Wyplosz B, Derradji O, Hong E, et al. Low immunogenicity of quadrivalent meningococcal vaccines in solid organ transplant recipients. Transpl Infect Dis. 2015;17:322–7.

    Article  CAS  PubMed  Google Scholar 

  55. Mahler MB, Taur Y, Jean R, Kernan NA, Prockop SE, Small TN. Safety and immunogenicity of the tetravalent protein-conjugated meningococcal vaccine (MCV4) in recipients of related and unrelated allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012;18:141–55.

    Article  CAS  Google Scholar 

  56. Food and Drug Administration. Product approval information: package insert. Heplisav-B. Silver Spring: US Department of Health and Human Services, Food and Drug Administration; 2018. https://www.fda.gov/BiologicsBloodVaccines/ApprovedProducts/ucm584752.htm

  57. Huprikar S, Danziger-Isakov L, Ahn J, et al. Solid organ transplantation from hepatitis B virus-positive donors: consensus guidelines for recipient management. Am J Transplant. 2015;15:1162–72.

    Article  CAS  PubMed  Google Scholar 

  58. Skagen CL, Jou JH, Said A. Risk of de novo hepatitis in liver recipients from hepatitis-B core antibody-positive grafts – a systematic analysis. Clin Transpl. 2011;25:E243–9.

    Article  Google Scholar 

  59. Lefebure AF, Verpooten GA, Couttenye MM, De Broe ME. Immunogenicity of a recombinant DNA hepatitis B vaccine in renal transplant recipients. Vaccine. 1993;11:397–9.

    Article  CAS  PubMed  Google Scholar 

  60. Loinaz C, de Juanes JR, Gonzalez EM, et al. Hepatitis B vaccination results in 140 liver transplant recipients. Hepato-Gastroenterology. 1997;44:235–8.

    CAS  PubMed  Google Scholar 

  61. Stevens CE, Alter HJ, Taylor PE, Zang EA, Harley EJ, Szmuness W. Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. N Engl J Med. 1984;311:496–501.

    Article  CAS  PubMed  Google Scholar 

  62. Horlander JC, Boyle N, Manam R, et al. Vaccination against hepatitis B in patients with chronic liver disease awaiting liver transplantation. Am J Med Sci. 1999;318:304–7.

    Article  CAS  PubMed  Google Scholar 

  63. Mallet V, van Bommel F, Doerig C, et al. Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5). Lancet Infect Dis. 2016;16:606–17.

    Article  PubMed  Google Scholar 

  64. Shouval D, Ilan Y. Transplantation of hepatitis B immune lymphocytes as means for adoptive transfer of immunity to hepatitis B virus. J Hepatol. 1995;23:98–101.

    Article  CAS  PubMed  Google Scholar 

  65. Jaffe D, Papadopoulos EB, Young JW, et al. Immunogenicity of recombinant hepatitis B vaccine (rHBV) in recipients of unrelated or related allogeneic hematopoietic cell (HC) transplants. Blood. 2006;108:2470–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2006;55:1–23.

    Google Scholar 

  67. Arslan M, Wiesner RH, Poterucha JJ, Zein NN. Safety and efficacy of hepatitis A vaccination in liver transplant recipients. Transplantation. 2001;72:272–6.

    Article  CAS  PubMed  Google Scholar 

  68. Arslan M, Wiesner RH, Poterucha JJ, Gross JB Jr, Zein NN. Hepatitis A antibodies in liver transplant recipients: evidence for loss of immunity posttransplantation. Liver Transpl. 2000;6:191–5.

    Article  CAS  PubMed  Google Scholar 

  69. Madeleine MM, Finch JL, Lynch CF, Goodman MT, Engels EA. HPV-related cancers after solid organ transplantation in the US. Am J Transplant. 2013;13:3202–9. https://doi.org/10.1111/ajt.12472.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Kumar D, Unger ER, Paonicker G, Medvedev P, Wilson L, Humar A. Immunogenicity of quadrivalent human papillomavirus vaccine in organ transplant recipients. Am J Transplant. 2013;13:2411–7. https://doi.org/10.1111/ajt.12329.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Munoz N, Manalastas R Jr, Pitisuttithum P, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial. Lancet. 2009;373:1949–57.

    Article  CAS  PubMed  Google Scholar 

  72. Gomez-Lobo V, Whyte T, Kaufman S, Torres C, Moudgil A. Immunogenicity of a prophylactic quadrivalent human papillomavirus LI virus-like particle vaccine in male and female adolescent transplant recipients. Pediatr Transplant. 2014;18:310–5.

    Article  CAS  PubMed  Google Scholar 

  73. Nelson DR, Neu AM, Abraham A, Amaral S, Batisky D, Fadrowski JJ. Immunogenicity of human papillomavirus recombinant vaccine in children with CKD. Clin J Am Soc Nephrol. 2016;11:776–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Petrosky E, Bocchini JA Jr, Hariri S, et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2015;64:300–4.

    PubMed  PubMed Central  Google Scholar 

  75. Savani BN, Stratton P, Shenoy A, Kozanas E, Goodman S, Barrett AJ. Increased risk of cervical dysplasia in long-term survivors of allogeneic stem cell transplantation – implications for screening and HPV vaccination. Biol Blood Marrow Transplant. 2008;14:1072–5. https://doi.org/10.1016/j.bbmt.2008.07.005.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Lawrence R, Gershon AA, Holzman R, Steinberg SP. The risk of zoster after varicella vaccination in children with leukemia. N Engl J Med. 1988;318:543–8.

    Article  CAS  PubMed  Google Scholar 

  77. Heininger U, Seward JF. Varicella. Lancet. 2006;368:1365–76.

    Article  PubMed  Google Scholar 

  78. Rawson H, Crampin A, Noah N. Deaths from chickenpox in England and Wales 1997–7: analysis of routine mortality data. BMJ. 2001;323:1091–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Posfay-Barbe KM, Pittet LF, Sottas C, et al. Varicella-zoster immunization in pediatric liver transplant recipients: safe and immunogenic. Am J Transplant. 2012;12:2974–85.

    Article  CAS  PubMed  Google Scholar 

  80. Weinberg A, Horslen SP, Kaufman SS, et al. Safety and immunogenicity of varicella-zoster virus vaccine in pediatric liver and intestine transplant recipients. Am J Transplant. 2006;6:565–8.

    Article  CAS  PubMed  Google Scholar 

  81. Kraft JN, Shaw JC. Varicella infection caused by Oka strain vaccine in a heart transplant recipient. Arch Dermatol. 2006;142:943–5.

    Article  PubMed  Google Scholar 

  82. Levitsky J, Te HS, Faust TW, Cohen SM. Varicella infection following varicella vaccination in a liver transplant recipient. Am J Transplant. 2002;2:880–2.

    Article  PubMed  Google Scholar 

  83. Locksley RM, Flournoy N, Sullivan KM, Meyers JD. Infection with varicella-zoster virus after marrow transplantation. J Infect Dis. 1985;152:1172–81.

    Article  CAS  PubMed  Google Scholar 

  84. Sasadeusz J, Prince HM, Schwarer A, et al. Immunogenicity and safety of a two-dose live attenuated varicella vaccine given to adults following autologous hematopoietic stem cell transplantation. Transpl Infect Dis. 2014;16:1024–31. https://doi.org/10.1111/tid.12295.

    Article  CAS  PubMed  Google Scholar 

  85. Ezeanolue E, Harriman K, Hunter P, Kroger A, Pellegrini C. General best practice guidelines for immunization. Best practices guidance of the Advisory Committee on Immunization Practices (ACIP). http://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf

  86. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271–84.

    Article  CAS  PubMed  Google Scholar 

  87. Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372:2087–96.

    Article  PubMed  Google Scholar 

  88. Lal H, Cunningham AL, Kovac M, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375:1019–32.

    Article  PubMed  CAS  Google Scholar 

  89. Gourishankar S, McDermind JC, Jhangri GS, Preiksaitis JK. Herpes zoster infection following solid organ transplantation: incidence, risk factors, and outcomes in the current immunosuppressive era. Am J Transplant. 2004;4:108–15.

    Article  PubMed  Google Scholar 

  90. Manuel O, Kumar D, Singer LG, Cobos I, Humar A. Incidence and clinical characteristics of herpes zoster after lung transplantation. J Heart Lung Transpant. 2008;27:11–6.

    Article  Google Scholar 

  91. Kho M, Weimar W, Bovee D, Boer-Verschragen M, van der Eijk A, Van Besouw N. Vaccination to prevent the high herpes zoster incidence after renal transplantation [abstract]. Am J Transplant. 2015;15 (Suppl 3). https://atcmeetingabstracts.com/abstract/vaccination-to-prevent-the-high-herpes-zoster-incidence-after-renal-transplantation/

  92. Hamaguchi Y, Mori A, Uemura T, et al. Incidence and risk factors for herpes zoster in patients undergoing liver transplantation. Transpl Infect Dis. 2015;17:671–8.

    Article  CAS  PubMed  Google Scholar 

  93. Koo S, Gagne LS, Lee P, et al. Incidence and risk factors for herpes zoster following heart transplantation. Transpl Infect Dis. 2014;26:17–25.

    Article  Google Scholar 

  94. Miller G, Schaefer H, Yoder S, et al. A randomized, placebo-controlled phase I trial of live, attenuated herpes zoster vaccine in subjects with end-stage renal disease immunized prior to renal transplantation. Transpl Infect Dis. 2018;20:e12874. https://doi.org/10.1111/tid.12874.

    Article  CAS  PubMed  Google Scholar 

  95. Vink P, Ramon Torrell JM, Sanchez Fructuoso A, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in chronically immunosuppressed adults following renal transplant: a phase III, randomized clinical trial. Clin Infect Dis. 2019. pii: ciz177. https://doi.org/10.1093/cid/ciz177.

  96. Issa NC, Marty FM, Leblebjian H, et al. Live attenuated varicella-zoster vaccine in hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2014;20:279–87.

    Article  CAS  Google Scholar 

  97. Stadtmauer EA, Sullivan KM, Marty FM, et al. A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. Blood. 2014;124:2921–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Winston DJ, Mullane KM, Cornely OA, et al. Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391:2116–27.

    Article  PubMed  Google Scholar 

  99. Rand EB, McCarthy CA, Whitington PF. Measles vaccination after orthotopic liver transplantation. J Pediatr. 1993;123:87–9.

    Article  CAS  PubMed  Google Scholar 

  100. Kano H, Mizuta K, Sakakihara Y, et al. Efficacy and safety of immunization for pre- and post-liver transplant children. Transplantation. 2002;74:543–50.

    Article  CAS  PubMed  Google Scholar 

  101. Shinjoh M, Miyairi I, Hoshino K, Takahashi T, Nakayama T. Effective and safe immunizations with live-attenuated vaccines for children after living donor liver transplantation. Vaccine. 2008;26:6859–63.

    Article  PubMed  Google Scholar 

  102. Pittet LF, Verolet CM, McLin VA, et al. Multimodal safety assessment of measles-mumps-rubella vaccination after pediatric liver transplantation. Am J Transplant. 2019;19:844–54.

    Article  CAS  PubMed  Google Scholar 

  103. Ljungman P, Fridell E, Lonngvist B, et al. Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine. J Infect Dis. 1989;159:610–5.

    Article  CAS  PubMed  Google Scholar 

  104. Machado CM, Goncalves FB, Pannuti CS, Dulley FL, de Souza VA. Measles in bone marrow transplant recipients during an outbreak in Sao Paulo, Brazil. Blood. 2002;99:83–7.

    Article  CAS  PubMed  Google Scholar 

  105. Machado CM, de Souza VA, Sumita LM, da Rocha IF, Dulley FL, Pannuti CS. Early measles vaccination in bone marrow transplant recipients. Bone Marrow Transplant. 2005;35:787–91.

    Article  CAS  PubMed  Google Scholar 

  106. Sicre de Fontbrune F, Arnaud C, Cheminant M, et al. Immunogenicity and safety of yellow fever vaccine in allogeneic hematopoietic stem cell transplant recipients after withdrawal of immunosuppressive therapy. J Infect Dis. 2018;217:494–7.

    Article  CAS  PubMed  Google Scholar 

  107. Azevedo LS, Lasmar EP, Contieri FL, et al. Yellow fever vaccination in organ transplanted patients: is it safe? A multicenter study. Transpl Infect Dis. 2012;14:237–41.

    Article  CAS  PubMed  Google Scholar 

  108. Grohskopf LA, Sokolow LZ, Broder KR, Walter EB, Fry AM, Jernigan DB. Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices – United States, 2018–19 influenza season. MMWR Recomm Rep. 2018;67:1–20.

    Article  PubMed  PubMed Central  Google Scholar 

  109. Prevots DR, Burr RK, Sutter RW, Murphy TV. Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2000;49:1–22.

    CAS  PubMed  Google Scholar 

  110. Food and Drug Administration. Product approval information-licensing action, package insert: Rotateq (Rotavirus Vaccine, Live, Oral Pentavalent), Merck. Rockville: US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; 2006.

    Google Scholar 

  111. Food and Drug Administration. Rotarix clinical review. Rockville: US Department of Health and Human Services, Food and Drug Administration; 2008. http://www.fda.gov/cber/products/rotarix/rotarix031008.rev.pdf

Download references

Author information

Authors and Affiliations

  1. Transplant Infectious Diseases, University Health Network, Toronto, ON, Canada

    Shilpa R. Jain & Deepali Kumar

Authors
  1. Shilpa R. Jain
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Deepali Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Deepali Kumar .

Editor information

Editors and Affiliations

  1. Immunocompromised Host Service Division of Infectious Diseases, University of Miami Miller School of Medicine, Miami, FL, USA

    Michele I. Morris

  2. Transplant and Immunocompromised Host Infectious Diseases, Infectious Diseases Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

    Camille Nelson Kotton

  3. Division of Infectious Diseases, Duke University School of Medicine, Durham, NC, USA

    Cameron R. Wolfe

Section Editor information

  1. Division of Infectious Diseases, University of Miami Miller School of Medicine, Miami, FL, USA

    Michele I. Morris

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Jain, S.R., Kumar, D. (2021). Vaccination Strategies in Solid Organ and Stem Cell Transplant. In: Morris, M.I., Kotton, C.N., Wolfe, C.R. (eds) Emerging Transplant Infections. Springer, Cham. https://doi.org/10.1007/978-3-030-25869-6_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-25869-6_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-25868-9

  • Online ISBN: 978-3-030-25869-6

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation